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Disregulation of the proto-oncogene c-erbB-2 (also known as HER-2/neu) has been implicated in the aetiology of breast cancer. Since the pubication of a study linking c-erbB-2 to poor prognosis in breast cancer patients (Slamon et al., 1987) there have been many studies examining c-erbB-2 gene amplification, mRNA production and protein overexpression. Recent reviews have collated the results from over 50 studies and found a geneal agreement between them on the frequency of c-erbB-2 disegulation in terms of gene amplification and protein overexpresson, as measured by Southern blotting and immunohistocmistry spectively (Perren, 1991; Singleton & Strickler, 1992) . However, there are major differences in the association of c-erbB-2 disregulation with histopathological features and with prognosis, makcing its involvement in cancer development and progression difcult to determine. It (Frye et al., 1989 (Band et al., 1989) . The cell line UISO BCA1 was obtained from R.R. Mehta (University of Illinois, Chicago, IL, USA) and contains a 10-fold increase in the c-erbB-2 gene (Sasi et al., 1991 (Sambrook et al, 1989 ) and was mixed with control DNA derived from normal placenta (p258, one c-erb-B-2 gene copy), in proportions which gave a series of known c-erbB-2 copy numbers. The 21MT2 DNA was diluted to give c-erbB-2 copy numbers of 32, 24, 16, and 8, and UISO BCA1 was diuted to give copy numbers of 9, 6, 5, 4 and 3.
Immunohistochemistry
Overexpression of c-erbB-2 was ascertained using the rabbit polyclonal antibody, 21N, to the c-erbB-2 protein (Gullick et al., 1987) . Four micron sections of fixed tissue were dried at 56-C then stained in a thre-stag peroxidase-antiperoxidase technique (Sternberger, 1986 (Thompson et al., 1990) .
Twenty micrograms of total RNA was denatured with formamide and formldhyde at 55-C for 20 min and RNA species separated by edetophoresis on a 1.1% agarose gel. The RNA was tansferred to a nylon filter (hybond-N, Amersham, UK) by capillary action usng 10 x SSC and covaently fixed to the membrane using a UV tansillIuminator. To detect c-erbB-2 mRNA the filters were hybridised with 1107, a 1.7 kb fragment of v-erbB-2 (Semba et al., 1985) , according to the method of Church and Gilbert (1984) , washed to remove non-specifically attached probe and exposed to preflashed Kodak XAR film at -70C. Filters were stripped and reprobed with a-actin (Minty et al., 1981) as an internal control for loading. The extent of hybridisation of radiolabelled probe to the mRNA specis was determined using densitometry and expressed with respect to hybridisation to the actin probe.
Primes and the polymerase chain reaction Primers used in the differential PCR are listed in Table I . Tlhey were DNA sequences specific for interferon gamma (IFN-y150), c-erbB-2 and interferon beta (IFN-P). (Hubbard & Anderson, 1993 Satisfactory analysis of DNA ploidy by floA was obtained from 240 cancers. In 117 the phe diploid, and 123 were aneuploid or tetraploid. Th of amplification of c-erbB-2 in specimens assess cytometry was found to be highest in cancers diploid (60%), with lower percentages of aneu; and tetraploid (42%) cancers being amplil differences were not significant.
A third potentially confounding factor was th effect of normal cells present within the cancer haps reducing the detection frequency of amplifi proportion of amplified and non-amplified cases cancer ranked according to section cancer cellular in Figure 2 . Amplification was found in each of including those specimens in which cancer cells less than 25% of total cellularity. c-erbB-2 amplification and overexpression in breast Gene anplification determined by differential PCR 323 breast cancer specimens and 43 controls wer c-erbB-2 amplification using primers for c-erbBy150. Figure 3 shows representative PCR produc from fixed tissue specimens of three different canc DNA extracted by routine phenol/choroform from fresh tissue preserved at -70°C from oi cancers. Differential increase of c-erbB-2 product amplification is illustrated, with corresponding rat 1.4, 2.1 and 3.6 for the fixed cancer tissue, 3.7 f specimen 3 and 1.2 for control DNA. immunohistochemistry contained elevated levels of c-erbB-2 mRNA. Furthermore, 4 of 19 cases negative for immunohistochemistry also had elevated levels of mRNA; gene amplification determined by dPCR was present in two of these cases.
Discussion
This study with fixed paraffin-embedded tissue has demonstrated that dPCR is a highly sensitive technique for the detection of gene amplification and is also sufficiently robust to be applied to tumours of differing cellularity and DNA ploidy. For invasive cancers the frequency of gene amplification (55%) was considerably higher than anticipated from reports of conventional methods based on Southern or dot blotting techniques. In ten major studies of breast cancer, each assessing 100 or more cancer cases, the frequency of amplification varied between 17% and 23% (see review by Singleton & Strickler, 1992) . Because of the size of the disparity some initial comment on comparability of methods is appropriate.
Study of gene amplification is complicated by terminology for an increased gene number, which may be expressed as either a fold difference, increased copy number or both; fold difference is equated with copy number in some reports (Ali et al., 1988; Garcia et al., 1989) . We have assumed that the fold differences ascertained for the cell lines used in calibration of the dPCR are valid reflections of gene copy number, and have therefore expressed the altered dPCR ratio values as increased gene copy number. Owing to the arbitrary cutoff point for 'amplification' outwith the range observed in normals, dPCR would appear to lack the specificity to identify low copy number. Caution must be applied when ratio values are extrapolated to gene copy number in clinical cases. Experimental variation and approximations inherent to DNA analysis, including Southern or dot blotting techniques, may affect the precise relationship between classifications. Yet studies using Southern or dot blotting claim to detect increases as low as 2-fold without quoting the full range of values observed, the experimental variation in duplicate tests The overall frequency of amplification is 57% and overexpression 150o. (Borg et al., 1990) , while in this study 61% have ratio values of 2-3. There remains some uncertainty about the most appropriate cut-off point on which to base an amplified finding, but for the purposes of this evaluation a ratio value of 2 was chosen, as this was always above the values obtained for control samples. Raising the cut-off point to a ratio value of 2.5 would reduce the numbers amplified to levels equivalent to those previously reported. However, differences in amplifiation frequency depending on technique have also been observed in studies of the ovary. dPCR detected c-erbB-2 amplifiction in 40% of cancers (Hruza et al., 1993) ; in contrast, pevious studies by Southern blotting detected amplification in 1-26% of ovarian cancers (Slamon et al., 1989; Zang et al., 1989; Imyanitov et al., 1992) . This suggsts that there may be differences in sensitivity between these techniques. The possibility of artefactual elevation of dPCR ratio values in fixed tissue extracts was examined by comparing them with samples of DNA from the corresponding fresh tissue in a subset of cases, but we found no evidence for this (data not shown). There is also the issue of selection bias towards larger size of cancer where there is a requirment to submit tissue for extraction in DNA analysis. This does not apply to dPCR studies which, as in the present series, can be applid in a consecutive manner.
A higher degree of sensitivity than in the present study was claimed in a previous investigation of c-erbB-2 amplification using dPCR (Frye et al., 1989) . One extra copy (2-fold increase) was detectable, but that study used high-quality, homogeneous DNA derived from cell lnes in a single experiment. Further developments of the technique on clinical material classified amplfication in terms of fold differences, the most sensitive level detecting a 2-to 4-fold increase in c-erbB-2 product (Liu et al., 1992; Neubauer et al., 1992) .
Those studies used a complex algorithm of experimetal exclusions involing four different dPCR reactions resulting in a selce population of cancers, and detected c-erbB-2 amplification in 48% of in situ canrs and in 21 % of invasive cancers (Liu et al., 1992) . Details of interexperimental variation, ranges of dPCR ratio values and criteria for exclusion at each step of the algorithm were not stated. This makles direct comparison of amplation frequencies with the current study difficult. In addition Liu et al. (1992) restricted their series to stage H node-negative disease, whereas the present series was a consecutive group of operable cancer including both node-positive and nodenegative cases. However, despite the probklms of comparability, we consider that the technique as currently applied has major potential to give a valid but different perspetive of gene disregulation reklvant to study of the development and progression of ancer.
Detection of overexpression of c-erbB-2 by immunohistochemistry is subject to considerable variation between studies (Singleton & Strickler, 1993) in part because of the different primary antibodies, fixation methods, study set composition and criteria for assessing positive staining. The dilution used in this study of antibody 21N has been calibrated as detecting around 12 or more copies of c-erbB-2 (Gusterson et al., 1988) , therefore cases with an amplification of between five and 12 copies may appear to be immunonegative. Evidence from the present mRNA studies supports this lmitation to detecting expression as 21% of our immunonegative cases tested had increased mRNA levels. That changes in methods can affect the frequency of detection is evident from a recent report by Poller et al. (1992) , in which modification of fixation and immunohistochemical techniques increased the proportion of invasive cancers with c-erbB-2 overexpression to 39.7% from 15% (Lovekin et al., 1991) . As in other studie, we found good correlation between overexpression and amplification: 80% of immunopositive cancers had detectable gene ampliication. However, the ranges of gene copy values found by dPCR in immunopostive and immunonegative ancers of the current study set indicate that for both invasive and in situ cancers amplfication does not necessarily mean an equivalent overexpression, and some cases with strong immunostaining showed normal or modest icreases in gene copy numbers. This sugests that factors which cause overexpression of c-erbB-2 in the absence of gene amplication may also play a role when gene amplification is present.
The disparity in frequency of c-erbB-2 gene activation between in situ (around 44%) and invasive cancer (around 22%) noted in previous studies (see review by Singleton & Stickler, 1992) is considerably diminished in the present analysis, but the impliations for reklance in cancer progression are uncertain. An evaluation to test a hypothesis of cancer natural history in the breast by Alred et al. (1992) commented on c-erbB-2 overexpression in slce groups of 45 hyperplastic and dysplastic lesions as well as 708 in situ and invasive cancers. They concluded that abnormal activation of the gene was likely to be a sigiint but not the sole initiating factor for many cancers. The limitations of simple immunohistochemistry as a measure of disregulated gene activity have been recognised (Anderson, 1992; WynfordThomas, 1992) . Improved sensitivity of detecting abnormal gene activity through fluorescent (or other methods of) in situ hybridisation (Kallionemi et al., 1992; Smith et al., 1993 ) is hlkely to reveal considerably more about the heterogeneity and degree of gene disregulation within cell populations. The potential to explore mcnisms of gene control by further analysis of material slcted according to results of dPCR, Northern analysis and/or immuohistochemistry is however apparent from the results reported here.
The present tudies show that amplification of c-erbB-2 is a frequent event in breast cancer and that the relationship between gene amplification and overexpression may be complex. Although the insensitivity of current immunohistochemistry in detecting small inreases in protein is a factor compliating interpretation, it is neverteless likely that each part of the repication/transcription/translation process can be disregulated. Thus combininations of such events could account for the distribution of cases among the categories of Table II1 . Indeed, it appears that the fiequency of these various disorders of gene number and expression is not equivalent. A small percentage of cases overexpress c-erbB-2 in the absence of amplfication, while a larger number fail to show a detectable overexpression of the gene in the presence of amplification even though a small number of this group also have increased mRNA levels. Factors acting as promoters or suppressors of gene function may directly affect transcription regardless of the amplification status. Further direct evidence of factors affecting transcription comes from studies of breast cancer cell lines in which c-erbB-2 protein can be down-regulated by oestrogen complexed with its receptor (Russell and Hung, 1992) . Inreased c-erbB-2 mRNA levels resulting from elevated amounts of a transcription factor have also been observed in cancer cell ies which have no detectable gene ampltion (Hollywood & Hurst, 1993) . Other explanations of disorder include physical damage to the gene, mutation or the absence of promoters. This variety of biological events and consequences suggest that a more realistic model to evaluate c-erbB-2 disregulation in breast cancer must encompass a greater number of circumstances and consider the interaction of other biological processes. The potential to study these in subgroups of suitably characterised breast cancer cases is apparent. 
